Holiday thank-you coupon: enjoy 10% off all products

DENV4 Specific Neutra™ Antibody Products

Product list

Are you challenged by the antigenic complexity of the Dengue virus or the urgent need for type-specific therapeutics against DENV4? Creative Biolabs' DENV4 Specific Neutra™ Antibody Products empower your research with high-specificity, rigorously validated antibodies generated through advanced B-cell cloning and epitope-focused engineering, accelerating the development of precise diagnostics and effective countermeasures.

Introduction to DENV4

Dengue virus 4 (DENV4) represents one of the four serologically distinct lineages of the Flavivirus genus that pose a significant global public health burden. As an enveloped, positive-sense single-stranded RNA virus, its pathogenicity is dictated by a compact genome encoding three structural and seven non-structural proteins. Central to its infectivity and the host immune response is the Dengue virus 4 Envelope (DENV4-E) protein, which serves as the primary determinant for viral entry and the principal target for neutralizing antibodies.

  • Structural Insights

The DENV4 virion exhibits a sophisticated icosahedral symmetry. The DENV4-E protein is organized into three distinct structural domains (EDI, EDII, and EDIII) and exists primarily as head-to-tail homodimers on the surface of the mature particle. These dimers undergo a low-pH-induced conformational transition into trimeric forms within the endosome to facilitate membrane fusion. The structural integrity of DENV4-E is paramount for receptor-mediated endocytosis, making its surface-exposed epitopes critical for viral neutralization.

  • Resistance and Signaling Pathways

DENV4 infection initiates a complex cellular dialogue, primarily sensed by the pattern recognition receptors RIG-I and MDA5. This recognition triggers a robust type I interferon (IFN) response aimed at restricting viral replication. Concurrently, the massive production of viral proteins within the lumen of the endoplasmic reticulum (ER) induces significant ER stress, subsequently activating the Unfolded Protein Response (UPR). The virus has evolved various mechanisms to antagonize these pathways, balancing host cell survival with efficient viral progeny production.

TLR response to DENV infection. (OA Literature) Fig.1 Toll-like receptor activation in response to DENV infection.1

  • Clinical Impact

The clinical spectrum of DENV4 infection is broad, ranging from asymptomatic seroconversion to debilitating Dengue Fever (DF). However, the most severe manifestations-Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS)-are characterized by plasma leakage, severe hemorrhage, and organ impairment. These life-threatening conditions are frequently exacerbated by heterologous secondary infections through a mechanism known as Antibody-Dependent Enhancement (ADE).

Applications of Anti-DENV4 Neutralizing Antibodies

Pathogenesis and antibody-dependent dengue virus enhancing model. (OA Literature) Fig.2 Model of pathogenesis and antibody-mediated enhancement of dengue virus.2

  • Vaccine Efficacy and Immune Response Profiling

Neutralizing antibodies are the gold-standard correlate of protection for dengue vaccines. Our DENV4-specific Neutra™ antibodies are essential tools for quantifying type-specific neutralizing titers in vaccine sera using plaque reduction neutralization tests (PRNT) or high-throughput cell-based assays. This allows researchers to precisely evaluate vaccine-induced immunity, dissect the balance between protective and potentially enhancing antibody responses, and ensure vaccine candidates elicit robust, serotype-specific protection against DENV4.

  • Therapeutic Candidate Development and Mechanism of Action Studies

Monoclonal antibodies (mAbs) derived from or characterized using our specific reagents represent promising therapeutic candidates against DENV4. These antibodies can be employed in in vitro and in vivo models to demonstrate direct viral neutralization, block attachment to host cells, and assess protection against challenge. Furthermore, they are critical for studying neutralization kinetics, mapping escape mutations, and understanding the structural basis of epitope recognition to guide the engineering of next-generation, broad-spectrum or pan-serotype therapeutics with minimal ADE risk.

  • Advanced Diagnostic and Serological Surveillance

High-specificity anti-DENV4 antibodies enable the development of sensitive immunoassays, such as antigen-capture ELISA or lateral flow tests, for the early detection of DENV4 NS1 antigen in patient samples. Similarly, they are pivotal for serological assays that distinguish DENV4 infections from other flavivirus or heterologous dengue serotype infections. This is vital for accurate epidemiological surveillance, outbreak management, and patient diagnosis in endemic regions.

Our Anti-DENV4 Neutralizing Antibodies

Creative Biolabs delivers premium antibody solutions designed for the most demanding dengue research:

  • High Specificity and Low Cross-Reactivity: Our antibodies are meticulously selected and engineered to target unique DENV4 epitopes, minimizing cross-reactivity with other DENV serotypes or related flaviviruses, which is critical for reliable data.
  • Validated Neutralizing Activity: Each batch is functionally validated in relevant in vitro neutralization assays, providing confidence in their biological efficacy for your critical experiments.
  • Diverse Application Suitability: Optimized and tested for performance in key techniques including ELISA, Western Blot, Immunofluorescence, Flow Cytometry, and Neutralization Assays.
  • Consistent and Reproducible: Manufactured under stringent quality controls to ensure lot-to-lot consistency, a cornerstone for reproducible research and development.

With over two decades of expertise in virology and antibody development, Creative Biolabs is your dedicated partner in confronting complex infectious diseases like dengue. Our DENV4 Specific Neutra™ Antibody Products are more than just reagents; they are enabling components for discovery, designed to deliver precise, reliable data that accelerates your path from basic research to clinical application. Contact our scientific team today to discuss how our specific Neutra™ antibodies can be integrated into your workflow. We are here to provide detailed product specifications, application support, and custom solution strategies.

References

  1. Kayesh, Mohammad Enamul Hoque, Michinori Kohara, and Kyoko Tsukiyama-Kohara. "Recent insights into the molecular mechanism of toll-like receptor response to dengue virus infection." Frontiers in microbiology 12 (2021): 744233. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fmicb.2021.744233
  2. Sarker, Animesh, Nidhi Dhama, and Rinkoo Devi Gupta. "Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement." Frontiers in immunology 14 (2023): 1200195. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2023.1200195
Show More Close

Inquiry

Recombinant Anti-DENV4 Antibody (V3S-0522-YC7662) (CAT#: V3S-0522-YC7662)

Target: DENV4

Host Species: Mouse

Target Species: Dengue Virus (DENV),

Application: WB,ELISA,FuncS,

Inquiry

Recombinant Chimpanzee Anti-DENV4 Antibody (V3S-0522-YC7663) (CAT#: V3S-0522-YC7663)

Target: DENV4

Host Species: Chimpanzee

Target Species: Dengue Virus (DENV),

Application: WB,ELISA,FuncS,

For research use only, not directly for clinical use.


banner banner
© 2026 Creative Biolabs. All Rights Reserved.
antibody
ISO 9001 Certified - Creative Biolabs Quality Management System.
Online Inquiry